Skip to content
Maxcyte Logo
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Company History
    • Distributors
    • Careers
  • Non-Viral
  • Products
    • Instruments
      • ATx™
      • GTx™
      • STx™
      • VLx™
    • Consumables
      • RUO PAs
      • PA Accessories
      • GMP PAs
      • PA Order / Quote Request
  • Resources
    • Applications
      • Cell-Based Assays
      • Gene Editing
      • Primary Cells
      • Protein Production
      • Stem Cells
      • TCR/CAR T
    • Publications
      • Application Notes
      • Posters
      • Primary Literature
      • Product Literature
      • Webinars
      • White Papers
  • Investors
  • Events
    • News
      • MaxCyte® Minutes
      • Twitter feed
      • Virtual 3D booth
    • Events
      • Upcoming Events
      • Webinars Series
      • Event Calendar
  • Contact Us

resource

Previous Next
  • View Larger Image

Scalable Antibody Production from CHO Cell Line of Choice Using Flow Electroporation

ali2020-07-07T21:37:48+00:00May 12th, 2020|Comments Off on Scalable Antibody Production from CHO Cell Line of Choice Using Flow Electroporation

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditWhatsAppTumblrPinterestVkEmail

MaxCyte, Inc.

22 Firstfield Road, Suite 110
Gaithersburg, MD 20878
Tel: +1-301-944-1700
Fax: +1-301-944-1703

Life Sciences

Consumables

Careers

Applications

Investors

ExPERT Platform

Instruments

About Us

Resources

Contact Ustwitter linkedin
Legal | Privacy | Cookies | Social Media
MaxCyte®, ExPERT™, CARMA®, MaxCyte STx®, MaxCyte ATx®, MaxCyte GT®, MaxCyte VLX®, Flow Transfection®, Flow Electroporation®, Any Cell. Any Molecule. Any Scale®, GTx®, ATx®, and STx® logos are trademarks of MaxCyte, Inc. registered in the U.S. Patent and Trademark Office. ExPERT ATx™, ExPERT GTx™, ExPERT STx™, ExPERT VLx ™, MaxCyte GTx™ , VLx™ and Carma Cell Therapies™ are trademarks of MaxCyte, Inc.

Register to ISCT 2021

Engineering NK Cells

Case Study CRISPR mRNA & RNP Delivery

Case Study Gene Knock-in via Homology-directed Repair in Human iPSCs

Go to Top